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A healthy individual with a homozygous
PTCH2 frameshift variant: Are variants of
PTCH2 associated with nevoid basal cell
carcinoma syndrome?
M. Altaraihi1, K. Wadt1, J. Ek1, A. M. Gerdes1 and E. Ostergaard1
Abstract
Variants in PTCH2 have been described to be associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS). We
report a family with a healthy female who is homozygous for a frameshift variant, c.269delG, p.(Gly90Alafs*4), in PTCH2
and her heterozygous daughter. The variant predicts a frameshift and a premature stop codon. A summary of reported
heterozygous individuals with germline PTCH2 variants along with the existence of a healthy homozygous individual
question whether variants in PTCH2 are associated with NBCCS.
The Patched 2 (PTCH2) gene and its close homolog,
PTCH1, both encode transmembrane receptors of the
patched gene family in the sonic hedgehog pathway1.
Variants in the PTCH1 gene have been found to cause
nevoid basal cell carcinoma syndrome (NBCCS), also
known as Gorlin syndrome, with typical clinical mani-
festations of multiple basal cell carcinomas, odontogenic
keratocysts of the jaw, palmar and plantar pits, intracra-
nial ectopic calcification, facial dysmorphism (macro-
cephaly, cleft lip/palate), and eye anomalies (cataract,
pigmentary changes of the retinal epithelium and devel-
opmental defects)2,3. According to the NBCCS criteria of
Evans et al., at least two major and one minor criteria or
one major and three minor criteria must be fulfilled for a
patient to be diagnosed with NBCCS2,3. Autosomal
dominantly inherited NBCCS is transmitted with com-
plete penetrance and variable expressivity4,5. Large epi-
demiological studies of NBCCS report different ethnicity-
dependent penetrances of NBCCS: the most significant is
the lower prevalence of basal cell carcinoma in Japanese
NBCCS patients over 20 years of age (51.4%) compared to
American NBCCS patients (91%), Australian NBCCS
patients (85%), and British NBCCS patients (73%)2,6–8. It
has been suggested that PTCH2 variants can also cause
NBCCS, albeit with a milder phenotype9.
PTCH1 plays an important role in the sonic hedgehog
pathway, which is a regulator of patterning and develop-
ment in the embryo and adult. In brief, the pathway
comprises the sonic hedgehog ligand (Shh), PTCH1/
PTCH2 transmembrane receptors and the G protein-
coupled receptor Smoothened (Smo). The best-studied
member of the patched gene family, the PTCH1 receptor,
suppresses the release of Smo, but when Shh binds to the
PTCH1 receptor, this inhibition is alleviated, resulting in
Smo activation and translocation from the plasma mem-
brane to the primary cilium. While PTCH1 is the primary
Shh receptor, PTCH2 has a minor compensatory role in
Shh signal transduction, although its function is yet to be
fully understood10. Deficient PTCH1 and PTCH2 recep-
tors decrease the inhibition of Smo, which leads to
increased activity of transcription factors11.
We here present a healthy female homozygous for a
PTCH2 frameshift variant, and we therefore question the
association between PTCH2 variants and NBCCS.
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The clinical investigations were conducted according to
the principles expressed in the Declaration of Helsinki.
Both patients gave oral and written informed consent for
publication. Since the investigations were performed as
part of a diagnostic workup, we did not apply for ethics
approval.
Patient 1: An 18-year-old woman of Middle-Eastern
descent with consanguineous parents (1st cousins once
removed) was diagnosed with severe hypermobile Ehlers-
Danlos syndrome (EDS), congenital scoliosis, epilepsy,
and asthma at the age of 2 years (Fig. 1a). During the
following years, as a likely consequence of EDS, she
underwent three umbilical hernia operations. At 14 years
old, she was diagnosed with sleep apnea and began using
autoCPAP as treatment during the nights. Additionally,
she suffered from joint instability, which resulted in nearly
chronic subluxations of the bilateral carpometacarpal
joints. She was using orthotics and a walker to maintain
balance and stability while walking. Furthermore, the
patient was treated for chronic rhinosinusitis, weakened
mastication, and difficulty in swallowing. Lastly, the
patient had also been affected by migraine and fluctua-
tions of eye accommodation and refraction. To our
knowledge, she did not have any of the symptoms inclu-
ded in the diagnostic criteria for NBCCS. Whole-exome
sequencing was performed on blood from the patient.
Patient 2: The 39-year-old mother of patient 1 had been
diagnosed with hypermobility syndrome at the age of 34
years. Furthermore, she had been affected with recurrent
respiratory infections with hemoptysis for several years in
her early thirties. She reported no NBCSS manifestations
and was further examined for three major NBCCS cri-
teria. Skin examination by a dermatologist revealed no
basal cell carcinomas or palmar or plantar pits, and a
dental CT scan showed no cysts of the jaw. We refrained
from exposing the patient to unnecessary radiation, and
hence she was not examined for the fourth major criter-
ion, calcification of the falx cerebri. She did not have first-
degree relatives affected with NBCCS, which is the fifth
major criterion. To our knowledge, she did not fulfill any
of the minor criteria for NBCCS.
Variant analysis of whole-exome sequencing data
showed no pathogenic variants explaining the severe
Ehlers Danlos syndrome in patient 1. However, as an
incidental finding, a heterozygous variant, c.269delG, p.
(Gly90Alafs*4), was identified in exon 3 of PTCH2, lead-
ing to a frameshift and a premature stop codon. Sanger
sequencing of DNA from her mother showed homo-
zygosity for the c.269delG, p.(Gly90Alafs*4) variant
(Fig. 1b).
To our knowledge, the PTCH2 variant has not been
described previously, and it is not reported in ClinVar
Fig. 1 Pedigree and electropherogram of the family with a PTCH2 variant. a Pedigree of the family with a PTCH2 variant. b Electropherogram of
the PTCH2 c.269delG variant showing wild-type, heterozygous (patient 1) and homozygous (patient 2) individuals
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(https://www.ncbi.nlm.nih.gov/clinvar/) or the Genome
Aggregation Database (gnomAD)(http://gnomad.
broadinstitute.org), which comprises more than 245,000
alleles in this region.
Patient 2 with the homozygous PTCH2 variant had
worn traditional ethnic clothing covering the arms, legs,
and hair from a young age, and she had darkly pigmented
skin. Only her face and hands were exposed to ultraviolet
radiation, and hence the risk of developing basal cell
carcinomas could be considered low. However, ~80% of
reported basal cell carcinomas are located in the face,
head, and neck, and her risk of basal cell carcinoma is
therefore not negligible12.
It is notable that patient 1 is affected with scoliosis, as
40% of NBCCS cases are reported to have scoliosis13, but
this is not significant as scoliosis can occur as part of
many syndromic diseases.
Previously, three papers have described eight indivi-
duals, including six belonging to one family, with het-
erozygous PTCH2 variants (Table 1). Six individuals had
palmar or plantar pits, three individuals had keratocysts of
the jaw, two had bifid ribs, and one individual had mul-
tiple basal cell carcinomas. A newborn had embryonal
rhabdomyosarcoma14,15. None of the 10 PTCH2 indivi-
duals listed in Table 1 fulfilled the diagnostic criteria for
NBCCS proposed by Evans et al.3, whereas using the
diagnostic criteria proposed by Kimonis et al., 7 of the 10
individuals with PTCH2 variants would be diagnosed with
NBCCS, as these criteria demand only that two major
criteria be fulfilled7.
The reported PTCH2 variants (Table 1) included one 2-
bp deletion resulting in a frameshift and two missense
variants. One of the missense variants, c.1864C>T, p.
(His622Tyr), was found together with a PTCH1 variant in
a newborn with rhabdomyosarcoma, for whom no follow-
up was reported. This PTCH2 missense variant is very
frequent in gnomAD, with 26 homozygous individuals
reported, and in silico programs give a low probability of
the variant being pathogenic. The other missense variant
(c.2156G>A, p.(Arg719Gln)) was reported in six members
of one family, of whom none had NBCCS according to the
Evans criteria but all fulfilled the Kimonis diagnostic cri-
teria. The variant was reported in eight individuals in
gnomAD, and in silico predictions do not support its
pathogenicity. The frameshift variant, c.1172_1173delCT,
was found in 65 alleles, including one homozygous
individual.
A variety of PTCH1 variants cause NBCCS, including
missense, nonsense, frameshift, and splice site variants.
The gnomAD database reports 27 different loss of func-
tion (LOF) variants in PTCH1 (transcript size 8057 bp)
and 85 LOF variants in PTCH2 (transcript size 4298 bp),
of which one was reported as homozygous (/mentary
table S1). Assuming the variants are not on the same
alleles, these LOF variants are found in 59 individuals in
PTCH1 and in 480 individuals in PTCH2; hence, LOF
variants seem to be well-tolerated in PTCH2.
Analyses of knockout (KO) mice revealed that PTCH1 −/−
mutants were lethal at embryonic day 9.5 due to hyper-
activation of Shh signaling. By contrast, PTCH2 −/−mutants
were viable, fertile and apparently normal; however, alopecia,
epidermal hyperplasia, dermal hyperplasia, hair follicle loss,
and ulceration were frequently observed with progressing age
in PTCH2 −/− mutant male mice, whereas PTCH2 −/−
mutant female mice did not show any abnormalities. Neither
male nor female PTCH2 double KO mice developed basal
cell carcinomas10,16
Homozygosity for a frameshift variant in the PTCH2
gene does not seem to have caused any NBCCS mani-
festations in the patient reported here, and KO mice do
not display any NBCCS manifestations. Furthermore,
none of the previously reported PTCH2 individuals have
been diagnosed with NBCCS according to one of the
proposed sets of diagnostic criteria3. Finally, loss of
function variants in PTCH2 are frequent in population
studies.
These observations question whether variants in
PTCH2 are associated with NBCCS; if, however, it is the
case, the penetrance could be considered very low. Fur-
ther studies of larger cohorts of individuals with PTCH2
variants should clarify this.
HGV database
The relevant data from this Data Report are hosted at the Human Genome
Variation Database at https://doi.org/10.6084/m9.figshare.hgv.2534
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